ArticleFrontiers in oncology2025

Polatuzumab vedotin-R-CHP used for high-risk EBV-negative DLBCL-type post-transplant lymphoproliferative disorder in a long-term kidney transplant recipient: a case report.

Xiaoyu Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.